✦ LIBER ✦

Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer

✍ Scribed by Susan J. Ramus; Patricia A. Harrington; Carole Pye; Richard A. DiCioccio; Mark J. Cox; Kim Garlinghouse-Jones; Ingrid Oakley-Girvan; Ian J. Jacobs; Richard M. Hardy; Alice S. Whittemore; Bruce A.J. Ponder; M. Steven Piver; Paul D.P. Pharoah; Simon A. Gayther

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 403 KB
Volume: 28
Category: Article
ISSN: 1059-7794
DOI: 10.1002/humu.20599

No coin nor oath required. For personal study only.

✦ Synopsis

A total of 283 epithelial ovarian cancer families from the United Kingdom (UK) and the United States (US) were screened for coding sequence changes and large genomic alterations (rearrangements and deletions) in the BRCA1 and BRCA2 genes. Deleterious BRCA1 mutations were identified in 104 families (37%) and BRCA2 mutations in 25 families (9%). Of the 104 BRCA1 mutations, 12 were large genomic alterations; thus this type of change represented 12% of all BRCA1 mutations. Six families carried a previously described exon 13 duplication, known to be a UK founder mutation. The remaining six BRCA1 genomic alterations were previously unreported and comprised five deletions and an amplification of exon 15. One of the 25 BRCA2 mutations identified was a large genomic deletion of exons 19-20. The prevalence of BRCA1/2 mutations correlated with the extent of ovarian and breast cancer in families. Of 37 families containing more than two ovarian cancer cases and at least one breast cancer case with diagnosis at less than 60 years of age, 30 (81%) had a BRCA1/2 mutation. The mutation prevalence was appreciably less in families without breast cancer; mutations were found in only 38 out of 141 families (27%) containing two ovarian cancer cases only, and in 37 out of 59 families (63%) containing three or more ovarian cancer cases. These data indicate that BRCA1 and BRCA2 are the major susceptibility genes for ovarian cancer but that other susceptibility genes may exist. Finally, it is likely that these data will be of clinical importance for individuals in families with a history of epithelial ovarian cancer, in providing accurate estimates of their disease risks.

📜 SIMILAR VOLUMES

Ovarian cancer susceptibility alleles an

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

✍ Susan J. Ramus; Antonis C. Antoniou; Karoline B. Kuchenbaecker; Penny Soucy; Jon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB 👁 1 views

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of

Prevalence of BRCA1 and BRCA2 mutations

Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients

✍ Muhammad U. Rashid; Anbreen Zaidi; Diana Torres; Faisal Sultan; Axel Benner; Bil 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 312 KB 👁 2 views

## Abstract Among Asian countries, Pakistan has the highest rates of breast and ovarian cancer. To assess the contribution of the __BRCA1__ and __BRCA2__ germ line mutations to these high rates, we conducted the first study of 176 Pakistani breast and ovarian cancer patients, selected on family his

BRCA1 and BRCA2 mutations in breast/ovar

BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy

✍ L. Stuppia; P. Di Fulvio; G. Aceto; S. Pintor; S. Veschi; V. Gatta; A. Colosimo; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

We report on the screening of the entire BRCA1/BRCA2 coding sequence by SSCP, PTT, and direct sequencing in 68 Italian families with recurrent breast or ovarian cancer. For each investigated proband, the probability of being carrier of a BRCA1/BRCA2 mutation was evaluated using the BRCAPRO software.

Recurrent BRCA1 and BRCA2 germline mutat

Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: A founder mutation of BRCA1 identified in the Chinese population

✍ Ui-Soon Khoo; Kelvin Y.K. Chan; Annie N.Y. Cheung; W.C. Xue; D.H. Shen; K.Y. Fun 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

Previous mutational analysis for BRCA gene mutations in sporadic ovarian cancer occurring in Chinese patients in Hong Kong identified six germline BRCA1 mutations and one germline BRCA2 mutation, six of which were novel (Khoo et al., 2000). Knowledge of BRCA gene mutations in the Chinese population

Germline mutations of BRCA1 and BRCA2 in

Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families

✍ Hio Chung Kang; Il-Jin Kim; Jae-Hyun Park; Hyuk-Jun Kwon; Yong-Jin Won; Seung Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

Germline mutations in the BRCA1 and BRCA2 genes are responsible for the predisposition and development of familial breast and/or ovarian cancer. Most mutations of BRCA1 and BRCA2 associated with breast and/or ovarian cancer result in truncated proteins. To investigate the presence of BRCA1 and BRCA2

BRCA1 and BRCA2 mutation analysis in bre

BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland

✍ Magdalena Perkowska; Izabela BroŻek; Barbara Wysocka; Karin Haraldsson; Therese 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

Sixty high-risk breast and/or ovarian cancer families from North-Eastern Poland were screened for germline mutations in BRCA1 (MIM# 113705) and BRCA2 (MIM# 600185), using a combination of protein truncation test, denaturing high-performance liquid chromatography and direct sequencing. Sixteen (27%)